In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rigel’s High Science Bet

Executive Summary

In an era in which biotechs focus on specialty drugs in niche populations, Rigel has been building a portfolio that looks different from other biopharmas in terms of what goes in and how it goes out. Although the company is currently valued on the performance of fostamatinib, investors might do well to take notice of Rigel’s pipeline.

You may also be interested in...



R&D In Brief: Amgen, Arrowhead, Rigel, Coherus, Achillion

Arrowhead readies to advance its RNAi candidate for hepatitis B, while data on Achillion’s ‘3102 plus Sovaldi prepare the firm to start trials of its proprietary HCV combo. Coherus advances with a Humira biosimilar and Amgen will file Kyprolis for new indication despite failed study, while Rigel dry-eye failure has the firm refocusing on fostamatinib.

With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results

Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.

Korean Biopharma Today And Tomorrow: M&A, Investment, Governance

Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes. 

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV004010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel